The ingredient poised to transform the beverage sector
This represents the next evolution in the beverage industry
Villya seeks a single worldwide beverage collaborator for its patented cannabinoid technology that is quick-acting, uniform, and stable on the shelf.
Villya has acquired the technology designed to define the future of Hemp Derived beverages…”— William Miller
MELBOURNE, FL, UNITED STATES, August 12, 2026 /EINPresswire.com/ — Villya Pharmaceuticals has announced its move into the hemp-derived THC beverage market by acquiring cannabinoid intellectual property from Hythlayn Inc., which includes international patent application WO2025059525A1, “Compositions and Methods for Improving the Solubility of Cannabinoids and Endocannabinoids.” This acquisition establishes Villya as a technology and intellectual-property firm within the fast-changing market for hemp-derived Delta-9 THC drinks, THC seltzers, cannabis beverages, and next-generation adult drinks. Villya has no plans to produce beverages itself.
Rather, the company plans to pursue an exclusive licensing arrangement with a single large global beverage firm capable of bringing the technology to market on a large scale.
Tackling a Key Challenge with THC
Delta-9 THC is extremely water-repellent, which poses major difficulties when trying to include the cannabinoid in water-based beverages.
The intellectual property Villya has recently obtained is aimed at enhancing the solubility of cannabinoids and endocannabinoids, opening up potential uses in drinks and other cannabinoid delivery methods.
In Villya’s testing, its proprietary THC technology has shown a set of traits the company considers especially valuable for the beverage sector:
Onset of effects in roughly 3–4 minutes.
Even cannabinoid distribution.
Formulations that remain stable on the shelf without the cannabinoid precipitating out of solution.
Clearance from the body observed in Villya testing within about 24 hours.
Villya thinks the mix of fast onset, cannabinoid solubility, formulation stability, consistent dosing, and rapid clearance could produce a consumer experience markedly different from conventional edible cannabinoid items.
Designed for the Beverage Market Villya’s approach is intentional.
The company does not aim to construct bottling facilities, set up drink distribution channels, or compete against established beer, wine, and spirits companies.
Those capabilities already exist on a massive global scale. Villya intends to supply something distinct: The intellectual property and cannabinoid-delivery technology inside the beverage. For an appropriate global beverage company, an exclusive license could offer access to unique technology for creating fast-acting THC beverages, Delta-9 THC drinks, cannabis beverages, and next-generation adult drink alternatives, subject to relevant regulatory rules. Villya plans to assess strategic partnerships and eventually choose one major beverage partner for an exclusive licensing opportunity within the defined drink category.
A Significant Federal Deadline Is Approaching
Villya’s market entry occurs at a critical moment for the U.S. hemp-derived cannabinoid sector. On November 12, 2026, a revised federal definition of hemp is set to take effect, significantly altering the regulatory environment that aided the formation of today’s hemp-derived THC consumer market.
Under the updated definition, final hemp-derived cannabinoid products that contain more than 0.4 milligrams of combined total THC and cannabinoids with comparable effects per container would be excluded from the federal definition of hemp. This change could drastically reshape the existing hemp-derived Delta-9 THC beverage market. Villya believes this approaching regulatory shift makes advanced cannabinoid technology, intellectual property, formulation science, and regulatory strategy increasingly critical. The company does not assert that its technology bypasses federal or state THC restrictions. Instead, Villya aims to collaborate with a major beverage organization that can assess compliant commercialization routes as federal and state cannabinoid regulations change. Villya’s intellectual property focuses on cannabinoid solubility and delivery, rather than depending on any single regulatory classification. As the regulatory landscape evolves, Villya believes ownership of unique cannabinoid-delivery technology could grow more valuable.
From 3–4 Minutes to Approximately 24 Hours
The possible consumer experience represents another key element of Villya’s technology.
In testing of its proprietary THC formulation, Villya has observed effects starting in roughly three to four minutes. On the other end of the pharmacokinetic profile, the company has noted clearance from the user’s system within about 24 hours during its testing. Villya believes the combination of quick onset and observed rapid clearance justifies continued scientific and commercial investigation and could become a significant differentiator for future cannabinoid drinks. Individual metabolism, dosage, frequency of use, physiology, and drug-testing methods can affect THC detection. Therefore, Villya does not claim that using a Villya-formulated product ensures an individual will pass any specific drug test.
One Technology. One Global Beverage Partner
The biggest beverage companies worldwide have spent generations perfecting brands, manufacturing, packaging, distribution, and consumer experiences.
Cannabinoids introduce a separate challenge: Delivery technology. Villya believes its acquired intellectual property could offer a major beverage company a unique technology platform for engaging in whatever the next generation of regulated cannabinoid drinks becomes.
The company’s strategy is deliberately selective. Villya does not plan to widely license its beverage technology across competing global beverage firms. Instead, Villya intends to identify one global partner possessing the resources, brands, distribution infrastructure, and vision required to commercialize the technology at scale. For major beer, spirits, and beverage companies evaluating the future of THC drinks, hemp-derived Delta-9, cannabis beverages, functional drinks, and alcohol alternatives, Villya believes the opportunity goes beyond simply launching another product.
It is an opportunity to license the foundational technology. Villya holds the technology. Its future beverage partner provides the scale.
About Villya Pharmaceuticals
Villya Pharmaceuticals is a pharmaceutical technology and intellectual-property firm creating proprietary technologies aimed at improving the solubility, stability, bioavailability, and delivery of molecules that are difficult to formulate.
Through the acquisition of Hythlayn’s cannabinoid intellectual property, Villya is broadening its technology platform into the growing cannabinoid and hemp-derived THC beverage markets while pursuing strategic licensing opportunities with global industry partners.
website: www.villya.net
email: info@villya.net
Linkedin: https://www.linkedin.com/company/villya/?viewAsMember=true
*Images generated by chatgpt
William Miller
Villya
info@Villya.net
Visit us on social media:
LinkedIn
Instagram
